AI system evaluation governance, evidence collection and assurance research. Designed for ai safety teams; procurement functions; evaluation labs; scoped around source evidence and specific commercial or operational decisions.
AI safety evaluations and assurance is assessed through a defined research question rather than a generic claim of expertise. The proposed scope is ai system evaluation governance, evidence collection and assurance research. Work starts with the decision to be supported, the accountable decision-maker and the records available for review. The project brief identifies assumptions, evidence quality, access limits, relevant time horizons and matters requiring independent specialist validation.
Turn broad statements such as safe, reliable or aligned into measurable questions, representative datasets, severity scales and a documented test protocol. Record who selected each benchmark, whether it matches deployment conditions and which failures are outside the test.
Create a trace from system risks to testing methods, records, controls, review owner and outstanding gaps. The NIST AI RMF and GenAI Profile are voluntary reference frameworks; using them is not a substitute for accredited assessment or local statutory compliance.
Separate model evaluation, system-level adversarial assessment, security testing, governance review and ongoing monitoring. Arrange specialist testing and counsel engagement where required, and do not describe unpublished test results as independently validated.
The following are illustrative research formats, not assertions that a particular engagement or deliverable has already been completed.
The evaluation protocol matrix describes which evidence must be collected, its origin and review status, applicable commercial assumptions and the open decisions. It is intended to be reviewed with the project sponsor, not accepted as a certification, legal ruling or claim of future performance. Final scope depends on available records and agreed confidentiality arrangements.
The test evidence register describes which evidence must be collected, its origin and review status, applicable commercial assumptions and the open decisions. It is intended to be reviewed with the project sponsor, not accepted as a certification, legal ruling or claim of future performance. Final scope depends on available records and agreed confidentiality arrangements.
The risk-to-control traceability describes which evidence must be collected, its origin and review status, applicable commercial assumptions and the open decisions. It is intended to be reviewed with the project sponsor, not accepted as a certification, legal ruling or claim of future performance. Final scope depends on available records and agreed confidentiality arrangements.
Identify the precise business or technical decision, relevant evidence owner, published standard or source version and unresolved assumptions. Compare alternative interpretations, document the limitations of available data and specify what must be reviewed before a claim can be relied upon.
Identify the precise business or technical decision, relevant evidence owner, published standard or source version and unresolved assumptions. Compare alternative interpretations, document the limitations of available data and specify what must be reviewed before a claim can be relied upon.
Identify the precise business or technical decision, relevant evidence owner, published standard or source version and unresolved assumptions. Compare alternative interpretations, document the limitations of available data and specify what must be reviewed before a claim can be relied upon.
Describe the problem, intended use, decision owner and territorial scope; agree which facts would change the decision.
Map public standards, original contracts, product specifications, data, stakeholder interviews and available records. Timestamp versions and permissions.
Test alternatives against explicit criteria such as cost, novelty, operational impact, implementation dependencies and review effort.
Produce a source-linked memorandum or matrix with assumptions, limitations, specialist referral points and practical follow-up decisions.
For ai safety evaluations and assurance, the distinction between a vendor statement, published research and independently checked deployment evidence is essential. A product demonstration, research prototype or specification should be described as such. A source comparison must also establish dates and versions; developments in AI and compute change rapidly. Where a buyer plans procurement or investment, the final record should distinguish vendor promises, validated tests and assumptions requiring diligence.
Do not imply accredited AI safety certification, security testing or independent audit status.
External links are starting points for dated primary-source review, not substitutes for issue-specific verification.
Define the immediate decision, the relevant sources and stakeholders, the applicable time frame and the proposed evidence record. An initial scope may include testing claims, assurance reporting, red-team coordination.
No. Do not imply accredited AI safety certification, security testing or independent audit status. Professional opinions, certifications and specialist assessments require separately qualified parties and supporting facts.
Share the specific question, intended decision, technology or commercial context, relevant geography and expected output. Avoid sending confidential material before an appropriate process is agreed.